THE SHADOW OF DIABETES CARE IN OLDER ADULTS FRANCISCO DIAZ GNP-BC, CDE

Size: px
Start display at page:

Download "THE SHADOW OF DIABETES CARE IN OLDER ADULTS FRANCISCO DIAZ GNP-BC, CDE"

Transcription

1 THE SHADOW OF DIABETES CARE IN OLDER ADULTS FRANCISCO DIAZ GNP-BC, CDE

2 OBJECTIVES 1- Name 3 geriatric syndromes that impact DM care 2- Name the targets glycemic goals of care for older adults as recommended by American Diabetes Association 3- Name 3 anti-diabetes medications with high risk for hypoglycemia 4- Able to assess and to manage a hypoglycemic episode

3 INTRODUCTION million adult New Yorkers diagnosed with diabetes and 760,000 may not know that they have it 5 million have prediabetes diabetes related costs In NY $1.2 billion 2013 death attributed to DM; likely under counted because the identified cause would be cardiovascular disease but diabetes contributes to it Between death per 100,000 5 th cause of death in NY. (DiNapoli, T, 2015; CDC, 2015)

4 STANDARDS OF CARE FOR OLDER ADULTS American Diabetes Association Clin Diabetes 2018;36:14-37

5 GOALS & SETTING CRITERIA FOR OLDER ADULTS Adapted from: American Diabetes Association Clin Diabetes 2018;36: s119-s125 Patient Characteristics / Health Status Rationale A1c goal Healthy: Few coexisting chronic illnesses intact cognitive and functional status Complex / Intermediate: Multiple co-existing chronic illnesses or 2+ instrumental ADL impairments or mild- to moderate cognitive impairment Very complex/ poor health : LTC or end-stage chronic illnesses or moderate to- severe cognitive impairment or 2+ ADS dependencies Longer remaining life expectancy < 7.5% Fingerstick: mgdl Intermediate remaining life expectancy high treatment burden hypoglycemia vulnerability fall risk Limited remaining life expectancy Makes benefit uncertain <8.0% Finger stick: mgdl <8.5% Finger stick: mgdl

6 HYPOGLYCEMIA

7 IDENTIFICATION OF HYPOGLYCEMIA IN OLDER ADULTS Difficulties recognizing hypoglycemia in older adults Symptoms are not specific Easily misdiagnosed : stroke, vertigo, visual disturbance Atypical presentation e.g confusion or hypoactive delirium Unawareness of symptoms Patient who have impaired cognition are unable to communicate their feelings or symptoms

8 CONSEQUENCES OF HYPOGLYCEMIA Consequences of hypoglycemia Physical cognitive and functional dependence Recurrent falls Increased risks for fractures, frailty, mortality Behavioral changes : anxiety, fears, social Isolation Recurrent hospitalizations Increased risks for institutionalization

9 WHY SHOULD WE CARE?

10 HOW TO MANAGE HYPOGLYCEMIA 4 OUNCES X3 The National Diabetes Education Initiative

11 MEDICAL MANAGEMENT OF DIABETES CONSIDERING HYPOGLYCEMIA : PATOPHYSIOLOGY GLP1 SU TZD DDP4 INS GLP1 TZD SGLT2 GLP1 MET TZD GLP1 MET INS

12 Medical Management of diabetes : New Paradigm Abdul-Ghani,M and DeFronzo, R Diabetes Care 2017 Aug; 40(8):

13 ANTI DIABETES MEDICATIONS PER HYPOGLYCEMIA RISK

14 INSULINS

15 MONITORING

16 INSULIN PUMPS

17 APPS. DMES

18 CONSIDERATIONS: Type of Diabetes, Presence of complications, years with diabetes, past treatments Medications: how glucose levels will be affected AFTER taking the medications, inconsistent eating Episodes of hypoglycemia: provide events medication use, changes in eating pattern or type, increased activities, constitutional symptoms, was it asymptomatic. Measuring, keeping track of : foods, medications, exercise Before an appointment to a professional that will assess diabetes: check fasting, pre- meal and/ or 2 hours post meal for 2 days Emergency: glucagon pen, Personal Emergency Response system and Medic Alert Bracelet Possibility of driving, operating machinery, living alone, support system

19 CONCLUSION For older adults the benefits vs risks ratio of diabetes care is rather narrow; but now a days there are less riskier alternatives and possibilities to tailor it to those who would stand to benefit the least. Presence of hypoglycemia should be consider seriously, treated, prevented and, eventually, it should lead to reconsideration of the diabetes care to older adults.

20 RESOURCES General information: Diabetes Care Supplies, Medication Coverage : MLN/MLNMattersArticles/downloads/SE1008.pdf Sick Days & Emergency Preparedness:

21 SUPREME VIGILANCE

22 REFERENCES Abdelhafiz, A., Rodríguez-Mañas, L., Morley, J., & Sinclair, A. (2015). Hypoglycemia in Older People - A Less Well Recognized Risk Factor for Frailty. Aging And Disease, 6(2), Abdul-Ghani, M., & DeFronzo, R. (2017). Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm. Diabetes Care, 40(8), American Diabetes Association. (2017). 11. Older Adults: Standards of Medical Care in Diabetes Diabetes Care, 41(Supplement 1), S119-S Holst, J., & Orskov, C. (2004). The Incretin Approach for Diabetes Treatment: Modulation of Islet Hormone Release by GLP-1 Agonism. Diabetes, 53(Supplement 3), S197-S Kirsh, S., & Aron, D. (2011). Choosing Targets for Glycaemia, Blood Pressure and Low-Density Lipoprotein Cholesterol in Elderly Individuals with Diabetes Mellitus. Drugs & Aging, 28(12), Lipska, K., Krumholz, H., Soones, T., & Lee, S. (2016). Polypharmacy in the Aging Patient. JAMA, 315(10), Rawlings, K. (2013). Sonia Sotomayor: Her Life With Diabetes. Diabetes Forecast. Retrieved 11 February 2018, from Stats of the State of New York. (2018). Cdc.gov. Retrieved 25 February 2018, from

7/28/17. Objectives: Hypoglycemia Unawareness in the Geriatric Patient: A Safety Concern. Disclaimer:

7/28/17. Objectives: Hypoglycemia Unawareness in the Geriatric Patient: A Safety Concern. Disclaimer: Hypoglycemia Unawareness in the Geriatric Patient: A Safety Concern 29TH ANNUAL TNP CONFERENCE TRANSFORMING HEALTHCARE IN TEXAS SEPTEMBER 8, 2017 AUSTIN, TEXAS Kenneth Lowrance, DNP, APRN, CNS, FNP-BC,

More information

Diabetes Mellitus in Older Adults. Presenter Disclosure Information

Diabetes Mellitus in Older Adults. Presenter Disclosure Information Diabetes Mellitus in Older Adults Medha Munshi, M.D. Joslin Diabetes Center Beth Israel Deaconess Medical Center Harvard Medical School Presenter Disclosure Information Medha Munshi Research grant from

More information

Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND THE OLDER ADULT

Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND THE OLDER ADULT Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND THE OLDER ADULT Objectives u At conclusion of the presentation the participant will: 1. Discuss challenges to glycemic control unique in the older population

More information

LOW SUGAR: CAUSES, COMPLICATIONS AND MANAGEMENT OF HYPOGLYCEMIA

LOW SUGAR: CAUSES, COMPLICATIONS AND MANAGEMENT OF HYPOGLYCEMIA LOW SUGAR: CAUSES, COMPLICATIONS AND MANAGEMENT OF HYPOGLYCEMIA Anne Leake, PhD, APRN-Rx, BC-ADM ECHO Diabetes Learning Group 3/28/2018 Objectives 1. Identify common preventable causes of hypoglycemia

More information

Multiple Factors Should Be Considered When Setting a Glycemic Goal

Multiple Factors Should Be Considered When Setting a Glycemic Goal Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent

More information

It Happens Even in Type 2! When to Start Thinking Seriously About Hypoglycemia

It Happens Even in Type 2! When to Start Thinking Seriously About Hypoglycemia It Happens Even in Type 2! When to Start Thinking Seriously About Hypoglycemia Jacqueline LaManna, PhD, ANP BC, BC ADM, CDE Holly Divine, PharmD, BCACP, CGP, CDE, FAPhA Disclosures Dr. Jacqueline LaManna

More information

Special thanks to the EJC Foundation for their support of Sanford Center Geriatric Specialty Clinic

Special thanks to the EJC Foundation for their support of Sanford Center Geriatric Specialty Clinic Special thanks to the EJC Foundation for their support of Sanford Center Geriatric Specialty Clinic Sanford Center for Aging 775-784-4744 med.unr.edu/aging Diabetes Management Series: From Selfmanagement

More information

Learning Objectives. Impact of Diabetes II UPDATES IN TYPE 2 DIABETES. David Doriguzzi, PA-C

Learning Objectives. Impact of Diabetes II UPDATES IN TYPE 2 DIABETES. David Doriguzzi, PA-C UPDATES IN TYPE 2 DIABETES David Doriguzzi, PA-C Learning Objectives Upon completion of this educational activity, the participant should be able to: Overcome barriers and attitudes that limit Clinician/Patient

More information

Type 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions

Type 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic

More information

CASE A2 Managing Between-meal Hypoglycemia

CASE A2 Managing Between-meal Hypoglycemia Managing Between-meal Hypoglycemia 1 I would like to discuss this case of a patient who, overall, was doing well on her therapy until she made an important lifestyle change to lose weight. This is a common

More information

Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol

Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol *Please note that this guideline may not be appropriate for all patients

More information

Joshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South ALSHP Fall Meeting September 30, 2016

Joshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South ALSHP Fall Meeting September 30, 2016 Joshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South jjsettle@baptistfirst.org ALSHP Fall Meeting September 30, 2016 Objectives Describe the current information concerning newly approved

More information

Helpful Hints for Taking Care of Your Diabetes. Farahnaz Joarder, MD and Don Kain, MA, RD,CDE Harold Schnitzer Diabetes Health Center

Helpful Hints for Taking Care of Your Diabetes. Farahnaz Joarder, MD and Don Kain, MA, RD,CDE Harold Schnitzer Diabetes Health Center Helpful Hints for Taking Care of Your Diabetes Farahnaz Joarder, MD and Don Kain, MA, RD,CDE Harold Schnitzer Diabetes Health Center Objectives How big of a problem is diabetes? What is diabetes? How is

More information

Diabetes Management. Honoring Choice and Positive Outcomes for. in Older Adults. Nutrition Connection. by Brenda Richardson, MA, RDN, LD, CD, FAND

Diabetes Management. Honoring Choice and Positive Outcomes for. in Older Adults. Nutrition Connection. by Brenda Richardson, MA, RDN, LD, CD, FAND Nutrition Connection by Brenda Richardson, MA, RDN, LD, CD, FAND Honoring Choice and Positive Outcomes for Diabetes Management in Older Adults 16 As healthcare providers, we focus on offering support in

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Continuous Monitoring of Glucose in the Interstitial Fluid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: continuous_monitoring_of_glucose_in_the_interstitial_fluid

More information

Common Diabetes-related Terms

Common Diabetes-related Terms Common Diabetes-related Terms A1C An A1C test measures a person's average blood glucose level over two to three months. Hemoglobin is the part of a red blood cell that carries oxygen to the cells and sometimes

More information

Normal Fuel Metabolism Five phases of fuel homeostasis have been described A. Phase I is the fed state (0 to 3.9 hours after meal/food consumption),

Normal Fuel Metabolism Five phases of fuel homeostasis have been described A. Phase I is the fed state (0 to 3.9 hours after meal/food consumption), Normal Fuel Metabolism Five phases of fuel homeostasis have been described A. Phase I is the fed state (0 to 3.9 hours after meal/food consumption), in which blood glucose predominantly originates from

More information

Older Adults & Optimal Outcome. Individualizing Diabetes Management. Mary Moyer Janci BC-FNP BC-ADM CDE Teaching Associate Diabetes Care Center UWMC

Older Adults & Optimal Outcome. Individualizing Diabetes Management. Mary Moyer Janci BC-FNP BC-ADM CDE Teaching Associate Diabetes Care Center UWMC Older Adults & Optimal Outcome Individualizing Diabetes Management Mary Moyer Janci BC-FNP BC-ADM CDE Teaching Associate Diabetes Care Center UWMC What is Diabetes? METABOLIC DISEASE Food breakdown (carbohydrates,

More information

Objectives. The Problem. We ve come a LONG way, Innovations in Diabetes Care and Management. Barbara Walz, RN, BSN, CDE April 26, 2018

Objectives. The Problem. We ve come a LONG way, Innovations in Diabetes Care and Management. Barbara Walz, RN, BSN, CDE April 26, 2018 Objectives Innovations in Diabetes Care and Management Barbara Walz, RN, BSN, CDE April 26, 2018 1. Briefly discuss the history of diabetes management over the past 100 years 2. Describe the impact of

More information

INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE

INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE OBJECTIVES DESCRIBE INSULIN, INCLUDING WHERE IT COMES FROM AND WHAT IT DOES STATE THAT

More information

Incorporating CGM Into Clinical Decision Making. Etie Moghissi, MD, FACE Clinical Associate Professor, David Geffen School of Medicine UCLA

Incorporating CGM Into Clinical Decision Making. Etie Moghissi, MD, FACE Clinical Associate Professor, David Geffen School of Medicine UCLA Incorporating CGM Into Clinical Decision Making Etie Moghissi, MD, FACE Clinical Associate Professor, David Geffen School of Medicine UCLA 1 Limitations of Current Glucose Monitoring Methods A1c Standard

More information

The Many Faces of T2DM in Long-term Care Facilities

The Many Faces of T2DM in Long-term Care Facilities The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment

More information

Rationalizing Medications. Tan Jianming Senior Pharmacist KTPH

Rationalizing Medications. Tan Jianming Senior Pharmacist KTPH Rationalizing Medications Tan Jianming Senior Pharmacist KTPH + Older patients are more likely to: 2 Have multiple co-morbid diseases Have age-related physiological changes that result in a reduced tolerance

More information

NORTHEAST OHIO VA HEALTHCARE SYSTEM BEST PRACTICE RECOGNITION/MANAGEMENT OF HYPOGLYCEMIA

NORTHEAST OHIO VA HEALTHCARE SYSTEM BEST PRACTICE RECOGNITION/MANAGEMENT OF HYPOGLYCEMIA NORTHEAST OHIO VA HEALTHCARE SYSTEM BEST PRACTICE RECOGNITION/MANAGEMENT OF HYPOGLYCEMIA Joint Commission Inpatient Diabetes Team Sharon A. Watts DNP, FNP-BC, CDE Drina Nemes MSN, CNS, CRRN Amanda Pensiero

More information

Soliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide)

Soliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.48 Subject: Insulin GLP-1 Combinations Page: 1 of 5 Last Review Date: September 15, 2017 Insulin GLP-1

More information

Diabetes treatment by the algorithm

Diabetes treatment by the algorithm Diabetes treatment by the algorithm Joseph Dawley, M.D. Southwest Oklahoma Family Medicine Residency Oklahoma University Health Sciences Center Clinical Assistant Professor Objectives By the end of this

More information

DIABETES EDUCATION FOR HEALTH CARE SERIES

DIABETES EDUCATION FOR HEALTH CARE SERIES American Association of Diabetes Educators Provider is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. DIABETES EDUCATION

More information

Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?

Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of

More information

This program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.

This program applies to Commercial, GenPlus and Health Insurance Marketplace formularies. OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) Agonists [Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide extended-release), Tanzeum (albiglutide), Trulicity (dulaglutide),

More information

Objectives 10/11/2013. Diabetes- The Real Cost of Sugar. Diabetes 101: What is Diabetes. By Ruth Nekonchuk RD CDE LMNT

Objectives 10/11/2013. Diabetes- The Real Cost of Sugar. Diabetes 101: What is Diabetes. By Ruth Nekonchuk RD CDE LMNT Diabetes- The Real Cost of Sugar By Ruth Nekonchuk RD CDE LMNT Objectives To explain diabetes To explain the risks of diabetes To enumerate the cost of diabetes to our country To enumerate the cost of

More information

A Call to Action: Addressing Diabetes Medication Safety

A Call to Action: Addressing Diabetes Medication Safety A Call to Action: Addressing Diabetes Medication Safety Evan M. Klass, M.D., F.A.C.P. Senior Associate Dean, Statewide Initiatives Reducing ED visits for insulin induced hypoglycemia is a Healthy People

More information

Wayne Gravois, MD August 6, 2017

Wayne Gravois, MD August 6, 2017 Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion

More information

Common Drug Review Patient Group Input Submissions

Common Drug Review Patient Group Input Submissions Common Drug Review Patient Group Input Submissions empagliflozin and metformin (Synjardy) for Diabetes mellitus (Type 2) Patient group input submissions were received from the following patient groups.

More information

Continuous Glucose Monitoring Devices Pharmacy Policy

Continuous Glucose Monitoring Devices Pharmacy Policy Line of Business: All Line of Business Effective date: August 16, 2017 Revision date: August 16, 2017 Continuous Glucose Monitoring Devices Pharmacy Policy This policy has been developed through review

More information

Metabolic Syndrome: What s so big about BIG?

Metabolic Syndrome: What s so big about BIG? Tuesday, 10:00 11:30, A2 Objectives: Notes: Metabolic Syndrome: What s so big about BIG? Patrice Conrad pbconrad1@att.net 1. Identify advances in clinical assessment and management of selected healthcare

More information

Inpatient Management of Diabetes Mellitus. Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy

Inpatient Management of Diabetes Mellitus. Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy Inpatient Management of Diabetes Mellitus Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy 2 Disclosure Jessica Garza does not have any actual or potential conflicts of

More information

Diabetes Complications Recognition and Treatment

Diabetes Complications Recognition and Treatment Diabetes Complications Recognition and Treatment Edward Shahady MD, FAAFP, ABCL Clinical Professor Family Medicine Medical Director Diabetes Master Clinician Program Diabetes is the most difficult of all

More information

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics. DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this

More information

Multiple Small Feedings of the Mind: Diabetes. Sonja K Fredrickson, MD, BC-ADM March 7, 2014

Multiple Small Feedings of the Mind: Diabetes. Sonja K Fredrickson, MD, BC-ADM March 7, 2014 Multiple Small Feedings of the Mind: Diabetes Sonja K Fredrickson, MD, BC-ADM March 7, 2014 Question 1: Setting A1c Goals Describe the evidence based approach to determining the target HgbA1c in different

More information

Physical Activity/Exercise Prescription with Diabetes

Physical Activity/Exercise Prescription with Diabetes Physical Activity/Exercise Prescription with Diabetes B R AD H I NTERMEYER C E P A C SM S A NFORD H E ALTH C A RDIAC R E H AB A N D D I ABE TES E XE RCISE The adoption and maintenance of physical activity

More information

Welcome to BC PharmaCare's Public Input Questionnaire for drugs being reviewed under the B.C. Drug Review Process.

Welcome to BC PharmaCare's Public Input Questionnaire for drugs being reviewed under the B.C. Drug Review Process. Welcome to BC PharmaCare's Public Input Questionnaire for drugs being reviewed under the B.C. Drug Review Process. This questionnaire is for Jardiance (empagliflozin). Patient Groups have to register before

More information

Long-Term Care Updates

Long-Term Care Updates Long-Term Care Updates January 2019 By Kristina Nikl, PharmD Several recent studies evaluating the management of diabetes in older adults have concluded that 25-52% of elderly patients are currently being

More information

Frailty and Type 2 Diabetes Guidelines for clinicians

Frailty and Type 2 Diabetes Guidelines for clinicians H.G. WELLS PROJECT Frailty and Type 2 Diabetes Guidelines for clinicians Victoria Ruszala victoria.ruszala@nhs.net H.G. Wells Project team Dugal T, Partington E. Kernow CCG Diabetes and Frailty Guideline

More information

Diabetes Prevention (Managing Prediabetes)

Diabetes Prevention (Managing Prediabetes) IMPORTANCE OF FOCUS Although Prediabetes is not viewed as a clinical entity in its own right, it is a risk factor for diabetes and cardiovascular disease. It is estimated that approximately 1 in 3 U.S.

More information

Welcome to BC PharmaCare's Public Input Questionnaire for drugs being reviewed under the B.C. Drug Review Process.

Welcome to BC PharmaCare's Public Input Questionnaire for drugs being reviewed under the B.C. Drug Review Process. Welcome to BC PharmaCare's Public Input Questionnaire for drugs being reviewed under the B.C. Drug Review Process. This questionnaire is for Forxiga (dapagliflozin). Patient Groups have to register before

More information

DIABETES UPDATE 2018

DIABETES UPDATE 2018 DIABETES UPDATE 2018 Jerome V. Tolbert, M.D., Ph.D. Assistant Professor of Medicine Icahn School of Medicine at Mt. Sinai Division of Endocrinology and Bone Diseases 317 East 17 th Street New York, New

More information

Geriatrics and Cancer Care

Geriatrics and Cancer Care Geriatrics and Cancer Care Roger Wong, BMSc, MD, FRCPC, FACP Postgraduate Dean of Medical Education Clinical Professor, Division of Geriatric Medicine UBC Faculty of Medicine Disclosure No competing interests

More information

Why do we care? 20.8 million people. 70% of people with diabetes will die of cardiovascular disease. What is Diabetes?

Why do we care? 20.8 million people. 70% of people with diabetes will die of cardiovascular disease. What is Diabetes? What is Diabetes? Diabetes 101 Ginny Burns RN MEd CDE Diabetes mellitus is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin production, insulin action

More information

Meeting the Challenge of Inpatient Glycemic Management in the Non-Critical Care Setting

Meeting the Challenge of Inpatient Glycemic Management in the Non-Critical Care Setting Meeting the Challenge of Inpatient Glycemic Management in the Non-Critical Care Setting Jane Jeffrie Seley, DNP, MPH, GNP, BC-ADM, CDE, CDTC, FAAN, FAADE Diabetes Nurse Practitioner, Inpatient Diabetes

More information

9/16/2013. No Conflict of Interest to Disclose

9/16/2013. No Conflict of Interest to Disclose Catie Prinzing MSN, APRN, Clinical Nurse Specialist September 27, 2013 No Conflict of Interest to Disclose List key concepts to determining patient insulin doses during transitions in care Identify 5 points

More information

Standards of Care in Diabetes What's New? Veronica Brady, FNP-BC, PhD, BC-ADM,CDE Karmella Thomas, RD, LD,CDE

Standards of Care in Diabetes What's New? Veronica Brady, FNP-BC, PhD, BC-ADM,CDE Karmella Thomas, RD, LD,CDE Standards of Care in Diabetes 2016-- What's New? Veronica Brady, FNP-BC, PhD, BC-ADM,CDE Karmella Thomas, RD, LD,CDE Terminology No longer using the term diabetic. Diabetes does not define people. People

More information

Finding the sweet spot: Individualized targets for older adults with Type 2 DM

Finding the sweet spot: Individualized targets for older adults with Type 2 DM Finding the sweet spot: Individualized targets for older adults with Type 2 DM Samuel C. Durso, M.D., M.B.A. Mason F. Lord Professor of Medicine Director, Division of Geriatric Medicine and Gerontology

More information

GLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary

GLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy

More information

American Diabetes Association 2018 Guidelines Important Notable Points

American Diabetes Association 2018 Guidelines Important Notable Points American Diabetes Association 2018 Guidelines Important Notable Points The Standards of Medical Care in Diabetes-2018 by ADA include the most current evidencebased recommendations for diagnosing and treating

More information

Breaking the Cycle: Using Incretin-Based Therapies to Overcome Clinical Inertia in Type 2 Diabetes

Breaking the Cycle: Using Incretin-Based Therapies to Overcome Clinical Inertia in Type 2 Diabetes Breaking the Cycle: Using Incretin-Based Therapies to Overcome Clinical Inertia in Type 2 Diabetes Taking It to the Next Level: Pearls for Your Clinical Practice Thursday, April 23, 2009 6:00 AM - 8:00

More information

Clinical Value and Evidence of Continuous Glucose Monitoring

Clinical Value and Evidence of Continuous Glucose Monitoring Clinical Value and Evidence of Continuous Glucose Monitoring 9402313-012 Objective To review the clinical value and the recent clinical evidence for Professional and Personal CGM Key Points CGM reveals

More information

What s the Goal? Individualizing Glycemic Targets. Matthew Freeby M.D. December 3 rd, 2016

What s the Goal? Individualizing Glycemic Targets. Matthew Freeby M.D. December 3 rd, 2016 What s the Goal? Individualizing Glycemic Targets Matthew Freeby M.D. December 3 rd, 2016 Diabetes Mellitus: Complications and Co-Morbid Conditions Retinopathy Between 2005-2008, 28.5% of patients with

More information

New Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum

New Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum New Treatments for Type 2 diabetes Nandini Seevaratnam April 2016 Rushcliffe Patient Forum Overview Growing population of Type 2 diabetes Basic science on what goes wrong Current treatments Why there is

More information

DEMYSTIFYING INSULIN THERAPY

DEMYSTIFYING INSULIN THERAPY DEMYSTIFYING INSULIN THERAPY ASHLYN SMITH, PA-C ENDOCRINOLOGY ASSOCIATES SCOTTSDALE, AZ SECRETARY, AMERICAN SOCIETY OF ENDOCRINE PHYSICIAN ASSISTANTS ARIZONA STATE ASSOCIATION OF PHYSICIAN ASSISTANTS SPRING

More information

Adult Diabetes Clinician Guide NOVEMBER 2017

Adult Diabetes Clinician Guide NOVEMBER 2017 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Diabetes Clinician Guide Introduction NOVEMBER 2017 This evidence-based guideline summary is based on the 2017 KP National Diabetes Guideline.

More information

Team-Based Approaches to Help Older Adults With Type 2 Diabetes Achieve Individualized Glycemic Goals

Team-Based Approaches to Help Older Adults With Type 2 Diabetes Achieve Individualized Glycemic Goals Team-Based Approaches to Help Older Adults With Type 2 Diabetes Achieve Individualized Glycemic Goals 1. Which one of the agents listed here is widely considered the first-line therapy in type 2 diabetes

More information

Type 2 DM in Adolescents: Use of GLP-1 RA. Objectives. Scope of Problem: Obesity. Background. Pathophysiology of T2DM

Type 2 DM in Adolescents: Use of GLP-1 RA. Objectives. Scope of Problem: Obesity. Background. Pathophysiology of T2DM Type 2 DM in Adolescents: Use of GLP-1 RA Objectives Identify patients in the pediatric population with T2DM that would potentially benefit from the use of GLP-1 RA Discuss changes in glycemic outcomes

More information

Local Anesthesia for Dental Hygienists Session III. Altered Consciousness and Diabetes Michael E. O Brien, DDS and Frank S.

Local Anesthesia for Dental Hygienists Session III. Altered Consciousness and Diabetes Michael E. O Brien, DDS and Frank S. Altered Consciousness in General Dr. Michael E. O Brien Dr. Frank S. Drongowski Definitions Confusion - a mental state marked by disturbances in comprehension, understanding, and resulting in bewilderment

More information

Initiation and Titration of Insulin in Diabetes Mellitus Type 2

Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.

More information

Diabetes Management in New Brunswick Nursing Homes

Diabetes Management in New Brunswick Nursing Homes Diabetes Management in New Brunswick Nursing Homes Prepared by Dr. Angela McGibbon March, 2016 As the population ages and with the rising incidence of diabetes, there are increasing numbers of people with

More information

Insulin Prior Authorization with optional Quantity Limit Program Summary

Insulin Prior Authorization with optional Quantity Limit Program Summary Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)

More information

Agenda. Indications Different insulin preparations Insulin initiation Insulin intensification

Agenda. Indications Different insulin preparations Insulin initiation Insulin intensification Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations

More information

A Guidance Statement from the American College of Physicians

A Guidance Statement from the American College of Physicians Hemoglobin A1c Targets for Glycemic Control with Pharmacologic Therapy in Non-Pregnant Adults with Type 2 Diabetes Mellitus: A Guidance Statement from the American College of Physicians Timothy J. Wilt,

More information

ERBP Guideline on management of diabetics with advanced CKD

ERBP Guideline on management of diabetics with advanced CKD ERBP Guideline on management of diabetics with advanced CKD ERBP Mission improve the outcome of patients with kidney disease in a sustainable way, through enhancing the accessibility of knowledge on patient

More information

123 Are You Providing Evidence-Based Diabetes Care? - Martin

123 Are You Providing Evidence-Based Diabetes Care? - Martin Donna Martin, DNP, RN, CDE, CMSRN Lewis University Learner will be able to: Identify current inpatient standards of care for patients with diabetes Describe causes of hyperglycemia / hypoglycemia in the

More information

Self-Monitoring Blood Glucose (SMBG) Frequency & Pattern Tool

Self-Monitoring Blood Glucose (SMBG) Frequency & Pattern Tool Self-Monitoring Blood Glucose () Pattern Recommendation: Basal Insulin Only (To Target) NPH or long-acting analogue, typically given at. at least as often as is being given. Optional, less frequent can

More information

Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care

Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care Mary Jean Christian, MA, MBA, RD, CDE Diabetes Program Coordinator UC Irvine Health Hot Topics: Diabetes

More information

Non-insulin treatment in Type 1 DM Sang Yong Kim

Non-insulin treatment in Type 1 DM Sang Yong Kim Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay

More information

Diabetes: Three Core Deficits

Diabetes: Three Core Deficits Diabetes: Three Core Deficits Fat Cell Dysfunction Impaired Incretin Function Impaired Appetite Suppression Obesity and Insulin Resistance in Muscle and Liver Hyperglycemia Impaired Insulin Secretion Islet

More information

Diabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs

Diabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs Diabesity Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs Abdominal obesity Low HDL, high LDL, and high triglycerides HTN High blood glucose (F>100l,

More information

GLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration

GLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have

More information

Manage Diabetes with Small Changes

Manage Diabetes with Small Changes In This Issue: } Manage with Small Changes } The Role of Your Educator } Prediabetes: A Call to Action } Insulin and : Your Questions Answered Manage with Small Changes One man learns simple ways to keep

More information

Current Diabetes Care for Internists:2011

Current Diabetes Care for Internists:2011 Current Diabetes Care for Internists:2011 Petch Rawdaree, DM, MSc, DLSHTM Faculty of Medicine Vajira Hospital University of Bangkok Metropolis 19 th January 2011 ก ก 1. ก ก ก ก 2. ก ก ก ก ก 3. ก ก ก ก

More information

Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM

Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning

More information

Congestive Heart Failure: The Complication that Gets No Respect Richard J. Katz, MD Saturday, February 18, :30 a.m. 10:15 a.m.

Congestive Heart Failure: The Complication that Gets No Respect Richard J. Katz, MD Saturday, February 18, :30 a.m. 10:15 a.m. Congestive Heart Failure: The Complication that Gets No Respect Richard J. Katz, MD Saturday, February 18, 2017 9:30 a.m. 10:15 a.m. The prevalence of the combination of diabetes and both systolic and

More information

1. Continuous Glucose Monitoring

1. Continuous Glucose Monitoring 1. Continuous Glucose Monitoring 1. Physiology of interstitial fluid glucose 2. Comparison of CGM and self-monitored blood glucose (SMBG) data 3. Insulin dosing indication in BGM vs. CGM & the FDA 4. Protection

More information

Combination treatment for T2DM

Combination treatment for T2DM Combination treatment for T2DM Date of approval: December 2016 SAGLB.DIA.16.08.0657 Abbreviations ADA: American Diabetes Association CVD: Cardiovascular disease DPP-4: Dipeptidyl Peptidase-4 EASD: European

More information

Diabetes Education Columbus Community Hospital Stacy Biesel RN, CDE

Diabetes Education Columbus Community Hospital Stacy Biesel RN, CDE Diabetes Education Columbus Community Hospital Stacy Biesel RN, CDE Stacy Biesel, RN CDE Registered Nurse Certified Diabetes Educator Locations: Columbus Community Hospital Prairie Ridge Health Clinic

More information

DPP-4 inhibitor. The new class drug for Diabetes

DPP-4 inhibitor. The new class drug for Diabetes DPP-4 inhibitor The new class drug for Diabetes 1 Cause of Death in Korea 1 st ; Neoplasm 2 nd ; Cardiovascular Disease 3 rd ; Cerebrovascular Disease Diabetes 2 Incidence of Fatal or Nonfatal MI During

More information

VICTOSA and Renal impairment DR.R.S.SAJAD

VICTOSA and Renal impairment DR.R.S.SAJAD VICTOSA and Renal impairment DR.R.S.SAJAD February 2019 Main effect of GLP-1 is : Stimulating glucose dependent insulin release from the pancreatic islets. Slow gastric emptying Inhibit inappropriate

More information

OLD AND NEW DRUGS FOR CONTROLING DIABETES THERAPEUTIC CLASSES AND MECHANISM OF ACTION

OLD AND NEW DRUGS FOR CONTROLING DIABETES THERAPEUTIC CLASSES AND MECHANISM OF ACTION OLD AND NEW DRUGS FOR CONTROLING DIABETES THERAPEUTIC CLASSES AND MECHANISM OF ACTION Biljana Parapid, MD, PhD, FESC Belgrade University School of Medicine, Belgrade (Serbia) @biljana_parapid COI International

More information

DIABETES MANAGEMENT DISCHARGE COMMUNICATION (DM-DC) AUDIT TOOL

DIABETES MANAGEMENT DISCHARGE COMMUNICATION (DM-DC) AUDIT TOOL DIABETES MANAGEMENT DISCHARGE COMMUNICATION (DM-DC) AUDIT TOOL Facility: Date: Data Collector s name: Email/Phone: Purpose: To evaluate your facility practices regarding communication of requisite diabetes

More information

Hypoglycemia. Patient Education Diabetes Care Center. How to cope with low blood sugar. General Facts on Low Blood Sugar. Causes

Hypoglycemia. Patient Education Diabetes Care Center. How to cope with low blood sugar. General Facts on Low Blood Sugar. Causes Patient Education How to cope with low blood sugar Recognizing the causes and symptoms of hypoglycemia can help you prepare for and respond to this condition when it arises. General Facts on Low Blood

More information

Insulin Initiation and Intensification. Disclosure. Objectives

Insulin Initiation and Intensification. Disclosure. Objectives Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School

More information

In general: Hypoglycemia is common in insulin treated diabetes, but may also occur in people on oral medications, especially sulfonylureas/glinides.

In general: Hypoglycemia is common in insulin treated diabetes, but may also occur in people on oral medications, especially sulfonylureas/glinides. 1 2 3 In general: Hypoglycemia is common in insulin treated diabetes, but may also occur in people on oral medications, especially sulfonylureas/glinides. 4 Answer: b and c Many alcohol containing drinks

More information

Pharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17

Pharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17 Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)

More information

Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes

Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell

More information

MOVING ON... WITH DIABETES

MOVING ON... WITH DIABETES MOVING ON... WITH DIABETES ADOLESCENT KNOWLEDGE & SKILLS CHECKLIST (AGE 17-18 YRS) DIABETES EDUCATOR/TEAM USER GUIDE PURPOSE Provides adolescent self-assessment of learning needs prior to transition. Provides

More information

Clinical Overview of Combination Therapy with Sitagliptin and Metformin

Clinical Overview of Combination Therapy with Sitagliptin and Metformin Clinical Overview of Combination Therapy with Sitagliptin and Metformin 1 Contents Pathophysiology of type 2 diabetes and mechanism of action of sitagliptin Clinical data overview of sitagliptin: Monotherapy

More information

Diabetes Care Center Box 356176 1959 N.E. Pacific St. Seattle, WA 98195 206-598-4882 120457 University of Washington Medical Center Diabetes Care Center Arabic r02/2000 Patient Education Diabetes Care

More information

Updates in Diabetes Technology

Updates in Diabetes Technology Updates in Diabetes Technology Jessica Kirk, MSN, RN, CPN, CDE Nurse Manager, Endo ECHO No disclosures Disclosures 1 Objectives Distinguish patients appropriate for continuous glucose monitoring and insulin

More information

Multifactorial risk assessments and evidence-based interventions to address falls in primary care. Objectives. Importance

Multifactorial risk assessments and evidence-based interventions to address falls in primary care. Objectives. Importance Multifactorial risk assessments and evidence-based interventions to address falls in primary care Sarah Ross, DO, MS Assistant Professor Internal Medicine, Geriatrics Nicoleta Bugnariu, PT, PhD Associate

More information

Jennifer Loh, MD, FACE Chief of Endocrinology KP Hawaii AAMD of Medical Education, KP Hawaii

Jennifer Loh, MD, FACE Chief of Endocrinology KP Hawaii AAMD of Medical Education, KP Hawaii Individualized Diabetes Treatment for the Elderly Jennifer Loh, MD, FACE Chief of Endocrinology KP Hawaii AAMD of Medical Education, KP Hawaii Extremely Relevant Baby Boomers are aging! ¼ of people age

More information

Changing Diabetes: The time is now!

Changing Diabetes: The time is now! Midwest Cardiovascular Research Foundation Welcomes DANITA HARRISON, ARNP Ms. Harrison discloses speaking relationships with Lilly, Novo Nordisk and Pfizer. Changing Diabetes: The time is now! Danita Harrison

More information